In view of the recent COVID surge and RTPCR mandatory now for passengers from China and a few countries, what is the take on Diagnostic Companies?
Metropolis - tainted due to IT Raids and thus one has to be watchful of this company.
Dr Lal
Thyrocare etc
In case there is a jump in share price, shall we exit or Continue to hold as long-term prospects of Testing in India are Good. ( Various Tests, not only COVID related)
The best days (when they were re-rated) of the Diagnostic players are behind them.
Too much of disruption & intense competition in the bread & butter category of tests.
I don't foresee any upward valuation re-rating but the strong ones (Dr. Lal, Metropolis & Thyrocare) will continue to compound as operational efficiencies keep increasing for them coupled with increased awareness, penetration & most importantly, consolidation.
Check our bank nifty option tips single target and start making money like pro traders.
